Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8447848rdf:typepubmed:Citationlld:pubmed
pubmed-article:8447848lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:8447848lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:8447848lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:8447848lifeskim:mentionsumls-concept:C0060201lld:lifeskim
pubmed-article:8447848lifeskim:mentionsumls-concept:C1542147lld:lifeskim
pubmed-article:8447848pubmed:issue1lld:pubmed
pubmed-article:8447848pubmed:dateCreated1993-4-8lld:pubmed
pubmed-article:8447848pubmed:abstractTextThe pharmacokinetics of fentiazac (F, CAS 18046-21-4) and hydroxyfentiazac (OH-F) were estimated in 12 elderly (> 76 years). After an oral single dose of 200 mg F, the plasma and urine profiles were determined using high-performance liquid chromatography with a fluorescence detection. When compared to results obtained in young adults, the maximum plasma concentrations (5.4 +/- 1.9 mg/l) and-the time to reach them were identical. The terminal half-life (7.0 +/- 9.1 h) was longer, due to a slight increase of the apparent volume of distribution and a decrease of the elimination clearance. The findings suggest that the dosage regimen of this drug should be decreased in the elderly. Moreover, the variability of the pharmacokinetics being larger, individual adaptation of the daily dose should be performed.lld:pubmed
pubmed-article:8447848pubmed:languageenglld:pubmed
pubmed-article:8447848pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8447848pubmed:citationSubsetIMlld:pubmed
pubmed-article:8447848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8447848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8447848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8447848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8447848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8447848pubmed:statusMEDLINElld:pubmed
pubmed-article:8447848pubmed:monthJanlld:pubmed
pubmed-article:8447848pubmed:issn0004-4172lld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:BeckHHlld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:HouinGGlld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:CampistronGGlld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:TufenkjiA EAElld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:RochasM AMAlld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:GrislainLLlld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:AkbaralyJ PJPlld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:CoulaisYYlld:pubmed
pubmed-article:8447848pubmed:authorpubmed-author:LapeyreCClld:pubmed
pubmed-article:8447848pubmed:issnTypePrintlld:pubmed
pubmed-article:8447848pubmed:volume43lld:pubmed
pubmed-article:8447848pubmed:ownerNLMlld:pubmed
pubmed-article:8447848pubmed:authorsCompleteYlld:pubmed
pubmed-article:8447848pubmed:pagination50-3lld:pubmed
pubmed-article:8447848pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:meshHeadingpubmed-meshheading:8447848-...lld:pubmed
pubmed-article:8447848pubmed:year1993lld:pubmed
pubmed-article:8447848pubmed:articleTitlePharmacokinetic study of fentiazac and its main metabolite hydroxyfentiazac in the elderly.lld:pubmed
pubmed-article:8447848pubmed:affiliationUnité de Pharmacocinétique Clinique, Centre Hospitalier Régional Purpan, France.lld:pubmed
pubmed-article:8447848pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8447848pubmed:publicationTypeComparative Studylld:pubmed